Children treated with pegylated interferon alfa-2a±ribavirin for chronic hepatitis c

Journal of Pediatric Gastroenterology and Nutrition

Volumn 62, Issue 1, 2016, Pages 93-96

  Schwarz, Kathleen B ^a   Molleston, Jean P ^b   Jonas, Maureen M ^c   Wen, Jessica ^d   Murray, Karen F ^e   Rosenthal, Philip ^f   Gonzalez Peralta, Regino P ^g   Lobritto, Steven J ^h   Mogul, Douglas ^a   Pavlovic, Vedran ⁱ   Warne, Charles ⁱ   Wat, Cynthia ⁱ   Thompson, Bruce ^j  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e SEATTLE CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^h NewYork Presbyterian Hospital   (United States)

ⁱ ROCHE PRODUCTS LTD   (United Kingdom)

^j Clinical Trials & Surveys Corp   (United States)

more..

Author keywords

antiviral therapy; long term follow up; pediatric viral hepatitis; PEDS C study

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ANAMNESIS; ANTIVIRAL THERAPY; ARTICLE; CHILD; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COHORT ANALYSIS; COMPASSIONATE USE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENE; GENOTYPE; HUMAN; IL28B GENE; LABORATORY TEST; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIREMIA; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIREMIA;

EID: 84952690737     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000929     Document Type: Article

References (13)

1. Gower E, Estes CC, Hindman S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014:S45-57.
2. El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastro 2013;19:7880-8.
3. Schwarz KB, Gonzalez-Peralta RP, Murray KG, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastro 2011; 140:450-8.
4. Manns MP, Pockros PJ, Norkrans G, et al. Long-term clearance of hepatitis C virus following interferon a-2b or peginterferon a-2b, alone or in combination with ribavirin. J Viral Hepat 2013;20:524-9.
5. Rahman MZ, Ahmed DS, Masud H, et al. Sustained virological response after treatment in patients with chronic hepatitis C infection - A five year follow up. Bangladesh MRC Bull 2013;39:11-3.
6. Kelly DA, Haber B, Gonzalez-Peralta RP, et al. Durability of sustained response shown in pediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin. J Viral Hepat 2012; 19:263-70.
7. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
8. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
9. Indolfi G, Azzari C, Resti M, et al. Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children. World J Gastroenterol 2014;20:9245-52.
10. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
11. Jonas MM, Schwarz KB, Gonzalez-Peralta R, et al. Long-term growth outcomes in children treated for chronic hepatitis C. J Pediatr 2014;165:1252-4.
12. Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001;34:223-9.
13. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014;348:g3308.